NJ Bio Overview
- Year Founded
-
2018
- Status
-
Acquired/Merged
- Employees
-
135
- Latest Deal Type
-
Later Stage VC
- (In Progress)
- Latest Deal Amount
-
$10M
NJ Bio General Information
Description
Operator of a biotechnology and pharmaceutical contracting company intended to provide integrated chemistry and biology services. The company provides services such as multistep organic synthesis, medicinal chemistry, bioconjugation, antibody-drug conjugates and flow chemistry, enabling clients to accelerate their product development programs and research needs.
Contact Information
Website
www.njbio.com(Operating Subsidiary)
Corporate Office
- 350 Carter Road
- Princeton, NJ 08540
- United States
Corporate Office
- 350 Carter Road
- Princeton, NJ 08540
- United States
NJ Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC | 12-Aug-2025 | $10M | In Progress | Generating Revenue | ||
| 2. Merger/Acquisition | 20-Dec-2024 | Completed | Generating Revenue | |||
| 1. Seed Round | 09-Mar-2023 | $5.62M | $5.62M | Completed | Generating Revenue |
NJ Bio Patents
NJ Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025222127-A2 | Topoisomerase inhibitors, antibody drug conjugate linkers, methods of making, and methods of use thereof | Pending | 19-Apr-2024 | ||
| EP-4720075-A1 | Topoisomerase inhibitors, methods of making, and methods of use thereof | Pending | 26-May-2023 | ||
| US-20260315612-A1 | Topoisomerase inhibitors, methods of making, and methods of use thereof | Pending | 26-May-2023 | ||
| WO-2024248944-A1 | Topoisomerase inhibitors, methods of making, and methods of use thereof | Inactive | 26-May-2023 | ||
| EP-4558506-A1 | Hexacyclic topoisomerase inhibitors having cytotoxic activity on cancer cells | Pending | 22-Jul-2022 | C07D491/22 |
NJ Bio Signals
NJ Bio Acquisitions (1)
NJ Bio’s most recent deal was a Merger/Acquisition with L2P Research. The deal was made on 06-Nov-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| L2P Research | 06-Nov-2025 | Merger/Acquisition | Drug Discovery |
NJ Bio Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| L2P Research | Annville, PA | 2015 |
NJ Bio FAQs
-
When was NJ Bio founded?
NJ Bio was founded in 2018.
-
Where is NJ Bio headquartered?
NJ Bio is headquartered in Princeton, NJ.
-
What is the size of NJ Bio?
NJ Bio has 135 total employees.
-
What industry is NJ Bio in?
NJ Bio’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is NJ Bio a private or public company?
NJ Bio is a Private company.
-
What is NJ Bio’s current revenue?
The current revenue for NJ Bio is .
-
How much funding has NJ Bio raised over time?
NJ Bio has raised $5.62M.
-
When was NJ Bio acquired?
NJ Bio was acquired on 12-Aug-2025.
-
Who acquired NJ Bio?
NJ Bio was acquired by Cohance Lifesciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process